BioSpace News Archive

Business

Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

March 7, 2024
·
12 min read
Business

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Evoke Pharma, Inc. (NASDAQ: EVOK) today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes.

March 7, 2024
·
6 min read
Business

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

March 7, 2024
·
9 min read
Business

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.

March 7, 2024
·
16 min read
Business

Immersion Corporation Reports Fourth Quarter and Full Year 2023 Results

Immersion Corporation, a leading developer and provider of technologies for haptics, reported financial results for the fourth quarter and full year ended December 31, 2023.

March 7, 2024
·
10 min read
Business

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.

March 7, 2024
·
7 min read
Business

Medtronic announces cash dividend for fourth quarter of fiscal year 2024

The board of directors of Medtronic plc on Thursday, March 7, 2024, approved the company’s cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share.

March 7, 2024
·
2 min read
Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024

MorphoSys’ Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET to present the results for the financial year 2023 and provide an outlook for 2024.

March 7, 2024
·
5 min read
DBV Technologies Reports Full Year 2023 Financial Results and Business Update

DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, reported financial results for the full year 2023.

March 7, 2024
·
12 min read
Genetown

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Pyxis Oncology, Inc. (Nasdaq: PYXS) announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida.

March 7, 2024
·
3 min read